Literature DB >> 6213149

Patterns of renal injury in systemic lupus erythematosus: light and immunofluorescence microscopic observations.

E Grishman, M A Gerber, J Churg.   

Abstract

Light and immunofluorescent microscopic patterns of lupus nephritis in 203 biopsies, 1 nephrectomy, and 20 autopsies from 179 patients were analyzed. The latest World Health Organization (WHO) classification was used. Seventy patients had diffuse lupus nephritis, 43 mesangial, 19 membranous, 19 focal, and 16 minimal change; 2 patients had advanced sclerosing nephritis. Nine patients were difficult to classify by light microscopy, but 3 of these could be classified with the help of immunofluorescence microscopy. Strict definition, especially of category III (focal and segmental lupus nephritis) is important, since this lesion has a tendency to heal, and patients with few immune deposits outside the segmental lesions have a rather good prognosis. Category V (membranous lupus nephritis) should probably be limited to membranous lesions with pure subepithelial deposits or with subepithelial and mesangial deposits, while membranous changes associated with diffuse or focal proliferative lesions are better classified as Category IV (diffuse lupus nephritis). It was observed that steroid treatment reduces the amount of deposits, especially those in the subendothelial and mesangial locations. The amount of proliferation is also reduced, but in a considerable proportion of cases, it is replaced by sclerosis. Therefore, interpretation of biopsy patterns must take prior therapy into consideration. Immunofluorescence findings in the glomeruli correlated quite well with light microscopic patterns. Active interstitial inflammation, which is most common in diffuse lupus nephritis, was only observed in the presence of tubulointerstitial immune deposits. Acute arteritis was much more common in autopsy than in biopsy specimens pointing to its ominous nature. It was concluded that combined examination of biopsies by light and immunofluorescence microscopy as well as electron microscopy, and strict categorization of lesions are valuable diagnostic and prognostic aids. Their usefulness is considerably enhanced if certain clinical data, such as prior therapy are taken into consideration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213149

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy.

Authors:  R Cervera; O Viñas; M Ramos-Casals; J Font; M García-Carrasco; A Sisó; F Ramírez; Y Machuca; J Vives; M Ingelmo; R W Burlingame
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

2.  Identification and validation of lupus nephritis cases using administrative data.

Authors:  L B Chibnik; E M Massarotti; K H Costenbader
Journal:  Lupus       Date:  2010-02-23       Impact factor: 2.911

3.  Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients.

Authors:  S Buján; J Ordi-Ros; J Paredes; M Mauri; L Matas; J Cortés; M Vilardell
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

4.  Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients. Subgroup classification of SLE.

Authors:  J Antolin; M J Amerigo; A Cantabrana; A Roces; P Jimenez
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

5.  Renal cortical necrosis at presentation in a patient with systemic lupus erythematosus: an autopsy case report.

Authors:  Megha S Uppin; Liza Rajasekhar; H Swetha; V R Srinivasan; Aruna K Prayaga
Journal:  Clin Rheumatol       Date:  2010-02-19       Impact factor: 2.980

6.  Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.

Authors:  Andrea Becker-Merok; Manar Kalaaji; Kaia Haugbro; Cathrin Nikolaisen; Kirsten Nilsen; Ole Petter Rekvig; Johannes C Nossent
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.